You are here:Home-Antimicrobial Viewpoints


Getting the most out of antimicrobial surveillance
– by Mariana Castanheira

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Surveillance has been promoted as an important tool to monitor the prevalence of antimicrobial resistance. Beyond this purpose, surveillance is conducted to identify the increase in prevalence of certain pathogens,


Getting the most out of antimicrobial surveillance
– by Mariana Castanheira
2020-05-28T06:47:56+00:00


COVID-19 and antimicrobial resistance: Are there any unknowns that will become known?
– by Stephan Harbarth

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” COVID-19 represents an unprecedented public health crisis that will bring many novel insights. This worldwide disturbance will probably affect the epidemiology of antimicrobial resistance (AMR) in many different ways that


COVID-19 and antimicrobial resistance: Are there any unknowns that will become known?
– by Stephan Harbarth
2020-05-13T14:55:19+00:00


COVID-19 and its impact on antimicrobial stewardship
– by Andrew Seaton

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial stewardship (AMS) is a system-wide approach to guiding, promoting and overseeing the safe and judicious use of antimicrobials. An AMS programme aims to safeguard antimicrobials, especially antibiotics, for future


COVID-19 and its impact on antimicrobial stewardship
– by Andrew Seaton
2020-05-07T12:07:20+00:00


The critical need for alternative approaches to address antibiotic treatment failure
– by Bob Hancock

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The O’Neill report1 suggested that up to 10 million people will die from antibiotic resistant infections by 2050. This figure has been adopted by health authorities, researchers and the general


The critical need for alternative approaches to address antibiotic treatment failure
– by Bob Hancock
2020-05-07T14:02:41+00:00


COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever
– by Manica Balasegaram

Artikel auf Deutsch lesen Lire en français PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The spectre of an infectious disease pandemic killing tens of thousands of people across the globe is no longer a


COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever
– by Manica Balasegaram
2020-05-07T14:04:19+00:00


The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation
– by Ryan Cirz and Kevin Krause

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” There is a growing awareness that companies with newly approved antibiotics face substantial economic challenges. Yet we remain concerned that there is a general lack of understanding of the mechanics


The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation
– by Ryan Cirz and Kevin Krause
2020-05-07T14:08:12+00:00


Diagnostics to safeguard new and current antibiotics for gonorrhoea
– by Cassandra Kelly-Cirino and Cecilia Ferreyra

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Gonorrhoea and chlamydia are the two most common sexually transmitted infections (STIs) in the world, with a staggering 214 million new cases occurring in 2016 alone.1 While anyone having unprotected


Diagnostics to safeguard new and current antibiotics for gonorrhoea
– by Cassandra Kelly-Cirino and Cecilia Ferreyra
2020-05-07T14:05:13+00:00


On fireworks and finding ways to address drug-resistance in low- and middle-income countries
– by Ramanan Laxminarayan

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Every autumn the Diwali festival is celebrated with food, gifts and fireworks. Ramanan Laxminarayan, Chair of the Board of the Global Antibiotic Research and Development Partnership (GARDP) reflects on India’s


On fireworks and finding ways to address drug-resistance in low- and middle-income countries
– by Ramanan Laxminarayan
2020-05-07T14:05:31+00:00


Bringing antimicrobial research and development to Africa – the time is now
– by Greg Basarab and Kelly Chibale

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial resistance (AMR) has been an ongoing threat to public health in South Africa as well as other countries in Africa. Disturbingly, the burden in the continent from infectious diseases


Bringing antimicrobial research and development to Africa – the time is now
– by Greg Basarab and Kelly Chibale
2020-05-07T16:40:50+00:00


Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why
– by Tim Jinks

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial resistance has a language problem, and we’ve known it for a while. Back in 2015, Wellcome published research revealing that people in the UK have little awareness of the


Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why
– by Tim Jinks
2020-05-07T16:33:58+00:00


A new cephalosporin has been approved
– by Ursula Theuretzbacher

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” After approval of four new ß-lactamase inhibitor (BLI) combinations in the last five years, a new member of the ß-lactam class made it to the finish line. On November 14,


A new cephalosporin has been approved
– by Ursula Theuretzbacher
2020-05-07T16:34:04+00:00


Are new antibiotic combinations the solution to the AMR crisis?
– by Anthony Coates

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The traditional model for the development and marketing of new chemical entity (NCE) antibiotics has collapsed. The companies which develop NCEs for resistant bacteria struggle to survive in the market. NCE


Are new antibiotic combinations the solution to the AMR crisis?
– by Anthony Coates
2020-05-07T16:35:02+00:00


Lessons from a recent outbreak of carbapenem-resistant Klebsiella pneumoniae in a neonatal unit
– by Adrie Bekker

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Our hospital is a tertiary referral centre in South Africa that manages up to 8000 high-risk deliveries per year of which 45% of newborns are of low birth weight (<


Lessons from a recent outbreak of carbapenem-resistant Klebsiella pneumoniae in a neonatal unit
– by Adrie Bekker
2020-05-07T16:35:32+00:00


Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel?
– by Colm Leonard & Tracy Parker

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The Global Action Plan on antimicrobial resistance (AMR), endorsed at the World Health Assembly in May 2015, recognised the need for sustainable and increased investment in new medicines, diagnostic tools,


Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel?
– by Colm Leonard & Tracy Parker
2020-05-07T16:40:27+00:00


Addressing Gram-negative permeation & efflux evasion with a collaborative discovery tool
– by Wes Kim & Katie Prosen

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The antibiotics pipeline is insufficient to address the growing public health threat posed by Gram-negative ESKAPE pathogens—which are among the hardest to treat—and by other antibiotic-resistant bacteria. Of the 42


Addressing Gram-negative permeation & efflux evasion with a collaborative discovery tool
– by Wes Kim & Katie Prosen
2020-05-07T16:36:08+00:00


How to steward new antibiotics into low- and middle-income countries (LMICs)?
– by Marc Mendelson & Adrian Brink

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Despite the many health system challenges faced by resource-poor LMICs, access to new antibiotics used in the treatment of multi-drug resistant (MDR) and extensively-drug resistant (XDR) bacterial infections should be


How to steward new antibiotics into low- and middle-income countries (LMICs)?
– by Marc Mendelson & Adrian Brink
2020-05-07T16:36:40+00:00


The REPAIR Impact Fund: Reflections from the first year
– by Aleks Engel

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial resistance (AMR) is a massive and growing concern worldwide. What can stop it? It is a complex and far-reaching problem with no easy answers, but we are trying to


The REPAIR Impact Fund: Reflections from the first year
– by Aleks Engel
2020-05-07T16:37:09+00:00


Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance
– by Sarah Paulin and Peter Beyer

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The R&D pipeline for new antibacterials to treat increasingly resistant bacterial infections is virtually dry. Very few classes of new antibiotics in particular to treat Gram-negatives have come to the


Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance
– by Sarah Paulin and Peter Beyer
2020-05-07T16:37:42+00:00


Time to pull out all the stops in the fight against superbugs
– by Kevin Outterson

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Great progress on push incentives In the Review on Antimicrobial Resistance (AMR), Lord Jim O’Neill called for a Global AMR Fund with $2 billion over five years. In the past


Time to pull out all the stops in the fight against superbugs
– by Kevin Outterson
2020-05-07T16:38:32+00:00


Why we need to prioritize developing antibiotics for children
– by Manica Balasegaram

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” A question I’m frequently asked is “with the rise of drug-resistant infections, how does GARDP decide where to focus its efforts”? It’s a reasonable question. And our approach is simple.


Why we need to prioritize developing antibiotics for children
– by Manica Balasegaram
2020-05-07T16:23:32+00:00


Recent approvals – do they make a difference?
– by Ursula Theuretzbacher

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Six new antibiotics have been approved by the U.S. Food and Drug Administration (FDA) over the last four years. So, at a first glance it seems that there is renewed


Recent approvals – do they make a difference?
– by Ursula Theuretzbacher
2020-05-07T16:39:10+00:00


More than one model to stimulate antimicrobial drug development
– by Jim O’Neill

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” When I first started leading the AMR Review in 2014, I soon came to the conclusion that, if the current model wasn’t delivering new antimicrobial drugs, the solution was obvious:


More than one model to stimulate antimicrobial drug development
– by Jim O’Neill
2020-05-07T16:39:46+00:00

External blogs in the field

The views and opinions expressed in this blog are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP is not responsible for the content of external sites. John H. Rex: Solutions for Antimicrobial Resistance David Shlaes: Antibiotics - The Perfect Storm Longitude Prize - Blog The Center For Disease Dynamics, Economics & Policy (CDDEP)

External blogs in the field2019-03-01T11:51:02+00:00